Arrayit Corporation Adds 128 New Products to Its Life Sciences Tools Portfolio
Published: Aug 16, 2010
Arrayit microarrays, which are miniature glass substrates containing microscopic spots of genes and proteins, offer up to 10 times the sensitivity of competing platforms and allow researchers to diagnose as many as 100,000 patients on a single chip. These attributes provide a significant competitive advantage when studying complex biological pathways such as human disease. Arrayit provides a comprehensive microarray technology platform including VIP(TM) genotyping packages, biomarker discovery services, whole human genome chips, protein microarrays, microarray printing robots, microarray pins and printheads, fluorescence and colorimetric scanners, personal instruments, software products, glass substrate slides, purification kits, buffers and solutions, and many other products used by scientists and doctors on a daily basis.
Arrayit CEO and Chairman Rene Schena states, "The versatility and effectiveness of the Arrayit platform provides an ongoing opportunity for licensing and new product revenues for Arrayit Corporation, as we continue to support the expanding needs of the scientific community."
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Arrayit now offers over 800 products to a customer base of more than 10,000 clinics and research facilities, and more than 5,000 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises, including a broad network of international distributors. Please visit www.arrayit.com for more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect," "believe," and "should." Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 200 and Form 10-Q for the fiscal quarters ended March 31, 2010 and June 30, 2010.
CONTACT: Arrayit Corporation Investor Relations 408-744-1331 firstname.lastname@example.org